Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions

SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis

Argyris Tzouvelekis, Guoying Yu, Jose Herazo-Maya, Tony Woolard, Yi Zhang, Hojin Lee, Patty Lee, Erica Herzog, Anton Bennett, Naftali Kaminski
European Respiratory Journal 2016 48: OA4979; DOI: 10.1183/13993003.congress-2016.OA4979
Argyris Tzouvelekis
Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CTUnited States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guoying Yu
Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CTUnited States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose Herazo-Maya
Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CTUnited States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tony Woolard
Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CTUnited States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Zhang
Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CTUnited States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hojin Lee
Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CTUnited States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patty Lee
Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CTUnited States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erica Herzog
Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CTUnited States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anton Bennett
Pharmacology, Yale University, New Haven, CTUnited States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naftali Kaminski
Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CTUnited States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Rationale: Idiopathic Pulmonary Fibrosis (IPF) is a chronic fatal lung disease with dismal prognosis and ineffective treatment. The potential role of the ubiquitously expressed SH2 domain-containing-tyrosine phosphatase (SHP2) as a therapeutic target has not been studied in IPF

Objectives: To determine the role of SHP2 in Pulmonary Fibrosis.

Methods: The effects of SHP2 overexpression and inhibition on fibroblast response to pro-fibrotic stimuli were analyzed in-vitro in primary human and mouse lung fibroblasts and in-vivo in the bleomycin-model of lung fibrosis.

Results: SHP2 was downregulated in lungs derived from patients with IPF at the mRNA and protein level and immunolocalization studies revealed that SHP2 expression was absent within fibroblastic foci. Loss of SHP2 expression or activity was sufficient to induce fibroblast to myofibroblast differentiation in primary human lung fibroblasts. Overexpression of constitutively active SHP2 reduced the responsiveness of fibroblasts to pro-fibrotic stimuli, including significant reductions in cell survival and myofibroblast differentiation. SHP2 effects were mediated through deactivation of fibrosis-relevant tyrosine-kinase and serine/threonine-kinase signaling pathways. Mice carrying the Noonan-syndrome-associated gain-of-function SHP2 mutation (SHP2D61G/+) were resistant to bleomycin-induced pulmonary fibrosis. Restoration of SHP2 levels in-vivo through lentiviral delivery blunted bleomycin-induced pulmonary fibrosis.

Conclusions: Our data suggest that SHP2 is an important regulator of fibroblast homeostasis. Augmentation of SHP2 activity or expression should be investigated as a novel therapeutic strategy for IPF.

  • Idiopathic pulmonary fibrosis
  • Cell biology
  • Interstitial lung disease
  • Copyright ©the authors 2016
Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis
Argyris Tzouvelekis, Guoying Yu, Jose Herazo-Maya, Tony Woolard, Yi Zhang, Hojin Lee, Patty Lee, Erica Herzog, Anton Bennett, Naftali Kaminski
European Respiratory Journal Sep 2016, 48 (suppl 60) OA4979; DOI: 10.1183/13993003.congress-2016.OA4979

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis
Argyris Tzouvelekis, Guoying Yu, Jose Herazo-Maya, Tony Woolard, Yi Zhang, Hojin Lee, Patty Lee, Erica Herzog, Anton Bennett, Naftali Kaminski
European Respiratory Journal Sep 2016, 48 (suppl 60) OA4979; DOI: 10.1183/13993003.congress-2016.OA4979
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • T lymphocytes in cigarette-smoke induced-emphysema and bronchial remodelling
  • MAPKAP kinase 2(MK2) expression is associated with severe asthma
  • Sputum levels of miR-145 and miR-338 in COPD, asthma and ACOS subjects
Show more 3.2 Airway Cell Biology and Immunopathology

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Collections
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2019 by the European Respiratory Society